Market Closed -
Nasdaq
21:00:00 02/05/2024 BST
|
5-day change
|
1st Jan Change
|
23.27
USD
|
+3.42%
|
|
+9.92%
|
-23.68%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
717.1
|
3,514
|
8,799
|
2,974
|
2,731
|
2,170
|
-
|
-
|
Enterprise Value (EV)
1 |
659.9
|
2,917
|
7,713
|
1,712
|
1,718
|
1,453
|
1,179
|
1,083
|
P/E ratio
|
-6.95
x
|
-22.7
x
|
-31.3
x
|
-5.66
x
|
-5.63
x
|
-4.21
x
|
-4.39
x
|
-4.22
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
16.6
x
|
60.6
x
|
266
x
|
57.1
x
|
75.3
x
|
43.2
x
|
41.4
x
|
18.1
x
|
EV / Revenue
|
15.3
x
|
50.3
x
|
233
x
|
32.8
x
|
47.4
x
|
28.9
x
|
22.5
x
|
9.03
x
|
EV / EBITDA
|
-6.55
x
|
-22.4
x
|
-29.6
x
|
-3.8
x
|
-3.39
x
|
-2.86
x
|
-2.35
x
|
-2.44
x
|
EV / FCF
|
-5.99
x
|
-54.5
x
|
-32.4
x
|
-4.94
x
|
-4.21
x
|
-3.82
x
|
-3.08
x
|
-3.19
x
|
FCF Yield
|
-16.7%
|
-1.83%
|
-3.08%
|
-20.3%
|
-23.7%
|
-26.2%
|
-32.5%
|
-31.3%
|
Price to Book
|
2.73
x
|
5.78
x
|
8.06
x
|
2.46
x
|
2.7
x
|
2.8
x
|
2.91
x
|
3.18
x
|
Nbr of stocks (in thousands)
|
48,882
|
64,594
|
74,419
|
85,234
|
89,555
|
96,439
|
-
|
-
|
Reference price
2 |
14.67
|
54.40
|
118.2
|
34.89
|
30.49
|
23.27
|
23.27
|
23.27
|
Announcement Date
|
27/02/20
|
25/02/21
|
24/02/22
|
23/02/23
|
22/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
43.1
|
57.99
|
33.05
|
52.12
|
36.28
|
50.25
|
52.42
|
119.9
|
EBITDA
1 |
-100.8
|
-130.3
|
-261
|
-450.6
|
-506.3
|
-508.5
|
-501.1
|
-443.7
|
EBIT
1 |
-106.4
|
-136.6
|
-267.8
|
-458.2
|
-515.3
|
-529.6
|
-554.8
|
-578.3
|
Operating Margin
|
-246.78%
|
-235.51%
|
-810.37%
|
-879.04%
|
-1,420.51%
|
-1,053.87%
|
-1,058.45%
|
-482.18%
|
Earnings before Tax (EBT)
1 |
-99.53
|
-134.2
|
-267.9
|
-474.2
|
-481.2
|
-522.6
|
-523.8
|
-561.2
|
Net income
1 |
-99.53
|
-134.2
|
-267.9
|
-474.2
|
-481.2
|
-511.8
|
-523.4
|
-557.9
|
Net margin
|
-230.92%
|
-231.46%
|
-810.49%
|
-909.78%
|
-1,326.51%
|
-1,018.46%
|
-998.55%
|
-465.15%
|
EPS
2 |
-2.110
|
-2.400
|
-3.780
|
-6.160
|
-5.420
|
-5.531
|
-5.302
|
-5.512
|
Free Cash Flow
1 |
-110.2
|
-53.5
|
-237.8
|
-346.8
|
-408.1
|
-379.9
|
-382.8
|
-339.4
|
FCF margin
|
-255.7%
|
-92.25%
|
-719.41%
|
-665.46%
|
-1,124.94%
|
-756.06%
|
-730.25%
|
-282.96%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
27/02/20
|
25/02/21
|
24/02/22
|
23/02/23
|
22/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
7.204
|
12.58
|
11.25
|
14.03
|
13.27
|
13.57
|
12.61
|
13.59
|
11.99
|
-1.917
|
9.065
|
19.13
|
9.758
|
9.531
|
17.66
|
EBITDA
|
-
|
-
|
-
|
-
|
-103.6
|
-108.1
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-71.99
|
-80.42
|
-144.2
|
-98.3
|
-105.5
|
-110.1
|
-112
|
-132.3
|
-131.1
|
-139.9
|
-134.8
|
-129.3
|
-139.8
|
-144
|
-145.3
|
Operating Margin
|
-999.35%
|
-639.03%
|
-1,281.96%
|
-700.65%
|
-795.49%
|
-811.07%
|
-888.13%
|
-973.47%
|
-1,093.29%
|
7,297.44%
|
-1,486.57%
|
-675.83%
|
-1,432.27%
|
-1,510.45%
|
-822.5%
|
Earnings before Tax (EBT)
1 |
-71.64
|
-81.24
|
-146.9
|
-100.7
|
-113.2
|
-113.4
|
-103.1
|
-123.7
|
-122.2
|
-132.2
|
-127.2
|
-123.9
|
-133.1
|
-138.2
|
-140.2
|
Net income
1 |
-71.64
|
-81.24
|
-146.9
|
-100.7
|
-113.2
|
-113.4
|
-103.1
|
-123.7
|
-122.2
|
-132.2
|
-125.3
|
-121.4
|
-130.9
|
-135.8
|
-140.2
|
Net margin
|
-994.5%
|
-645.56%
|
-1,305.3%
|
-717.59%
|
-853.53%
|
-835.53%
|
-818.07%
|
-909.82%
|
-1,019.21%
|
6,894.16%
|
-1,381.96%
|
-634.75%
|
-1,341.55%
|
-1,425.23%
|
-793.79%
|
EPS
2 |
-0.9700
|
-1.090
|
-1.960
|
-1.330
|
-1.490
|
-1.380
|
-1.170
|
-1.400
|
-1.380
|
-1.460
|
-1.371
|
-1.265
|
-1.402
|
-1.425
|
-1.406
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
04/11/21
|
24/02/22
|
05/05/22
|
04/08/22
|
03/11/22
|
23/02/23
|
04/05/23
|
03/08/23
|
09/11/23
|
22/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
57.2
|
597
|
1,086
|
1,262
|
1,012
|
717
|
991
|
1,087
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-110
|
-53.5
|
-238
|
-347
|
-408
|
-380
|
-383
|
-339
|
ROE (net income / shareholders' equity)
|
-36.3%
|
-33.7%
|
-
|
-41.7%
|
-42.1%
|
-61%
|
-70.8%
|
-56.3%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-33.7%
|
-34.1%
|
-47.4%
|
-39%
|
-77.7%
|
Assets
1 |
-
|
-
|
-
|
1,407
|
1,411
|
1,080
|
1,344
|
718
|
Book Value Per Share
2 |
5.380
|
9.410
|
14.70
|
14.20
|
11.30
|
8.320
|
8.000
|
7.310
|
Cash Flow per Share
2 |
-
|
-0.8900
|
-
|
-4.330
|
-4.440
|
-4.740
|
-3.000
|
-3.360
|
Capex
1 |
6.79
|
3.59
|
12.8
|
13.6
|
14
|
13.3
|
11.8
|
11.1
|
Capex / Sales
|
15.76%
|
6.18%
|
38.59%
|
26.01%
|
38.55%
|
26.52%
|
22.48%
|
9.25%
|
Announcement Date
|
27/02/20
|
25/02/21
|
24/02/22
|
23/02/23
|
22/02/24
|
-
|
-
|
-
|
Last Close Price
22.5
USD Average target price
71.16
USD Spread / Average Target +216.27% Consensus |
1st Jan change
|
Capi.
|
---|
| -23.68% | 2.17B | | +26.28% | 42.68B | | -3.99% | 42.4B | | +45.32% | 40.04B | | -6.20% | 28.31B | | +6.36% | 24.94B | | -21.47% | 18.96B | | +27.58% | 12.3B | | -2.75% | 11.95B | | -2.02% | 11.55B |
Other Biotechnology & Medical Research
|